Page 1199 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1164 ParT TEN Prevention and Therapy of Immunological Diseases

correction are being developed that may broaden indications 12. Bauer TR Jr, Hickstein DD. Gene therapy for leukocyte adhesion
for PIDs that may be treated by gene therapy (e.g., XHIM, XLA, deficiency. Curr Opin Mol Ther 2000;2:383–8.
etc.). Thus, the continued efforts of scientists and physicians to 13. Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and
develop gene therapy are leading to a new therapeutic modality, HLA-matched haemopoietic stem-cell transplantation in patients with
ideally to permanently and safely cure these diseases. chronic granulomatous disease: a prospective multicentre study. Lancet
2014;383:436–48. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/24161820.
ON THE HOrIZON 14. Santilli G, Almarza E, Brendel C, et al. Biochemical correction of X-CGD
• Continued expansion of the genetic types of PID being treated by by a novel chimeric promoter regulating high levels of transgene
gene addition using integrating vectors (e.g. other forms of SCID, expression in myeloid cells. Mol Ther 2011;19:122–32.
other forms of CGD, LAD, HLH, etc.). 15. De Ravin SS, Reik A, Liu P-Q, et al. Targeted gene addition in human
• Development of safe and effective marrow conditioning regimens CD34+ hematopoietic cells for correction of X-linked chronic
that are not chemotherapy-based (e.g. monoclonal antibodies) granulomatous disease. Nat Biotechnol. Nature Publishing Group
• Application of gene editing to broader spectrum of PIDs: e.g. X-linked 2016;(February):1–8. Available from: http://www.nature.com/doifinder/
agammaglobulinemia, X-linked Hyper-IgM syndrome (CD40 ligand 10.1038/nbt.3513.
deficiency), RAG1-deficient SCID, Gain of Function STAT1, IPEX). 16. Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, et al. WASp-deficient
• Understand the molecular pathogenesis of more PID (e.g. CVID, auto- B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp
immune) and develop effective gene therapy approaches. (Some may Med 2011;208:2033–42.
require more than just HSC correction, e.g. ataxia telangiectasia). 17. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the
• Production of autologous HSC by cellular reprogramming coupled to Wiskott-Aldrich syndrome. N Engl J Med 2010;363:1918–27.
effective expansion of HSC 18. Charrier S, Dupré L, Scaramuzza S, et al. Lentiviral vectors targeting
WASp expression to hematopoietic cells, efficiently transduce and correct
Please check your eBook at https://expertconsult.inkling.com/ cells from WAS patients. Gene Ther 2007;14:415–28. Available from:
for self-assessment questions. See inside cover for registration http://www.nature.com/doifinder/10.1038/sj.gt.3302863%5Cnpapers3://
details. publication/doi/10.1038/sj.gt.3302863.
19. Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical safety and
REFERENCES efficacy of human CD34+ Cells transduced with lentiviral vector for the
treatment of Wiskott-Aldrich syndrome. Mol Ther 2013;21:
1. Stewart FM, Crittenden RB, Lowry PA, et al. Long-term engraftment of 175–84. Available from: http://dx.doi.org/10.1038/mt.2012.23/
normal and post-5-fluorouracil murine marrow into normal nature06264.
nonmyeloablated mice. Blood 1993;81:2566–71. 20. Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following
2. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA
therapy for ADA- SCID: initial trial results after 4 years. Science 2015;313:1550–63. Available from: http://jama.jamanetwork.com/
1995;270:475–80. article.aspx?doi=10.1001/jama.2015.3253.
3. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine 21. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell
deaminase – deficient severe combined immune deficiency : clinical gene therapy in patients with Wiskott-Aldrich syndrome. Science
comparison of retroviral vectors and treatment plans. Blood 2013;341:1233151. Available from: http://www.ncbi.nlm.nih.gov/
2012;120:3635–46. pubmed/23845947.
4. Cicalese MP, Ferrua F, Castagnaro L, et al. Update on the safety and 22. Pala F, Morbach H, Castiello MC, et al. Lentiviral-mediated gene therapy
efficacy of retroviral gene therapy for immunodeficiency due to restores B cell tolerance in Wiskott-Aldrich syndrome patients. J Clin
adenosine deaminase deficiency. Blood 2016;128:45–54. Invest 2015;125:3941–51. Available from: http://www.pubmedcentral
5. Shaw KL, Sokolic R, Davila A, et al. Phase II clinical trial of gene therapy .nih.gov/articlerender.fcgi?artid=4607131&tool=pmcentrez&rendertype
for adenosine deaminase-deficient severe combined immune deficiency =abstract.
(ADA-SCID). Mol Ther 2014;22(Suppl. 1):S107. 23. Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene
6. Candotti F, Johnston JA, Puck JM, et al. Retroviral-mediated gene expression in hematopoietic lineages provides effective lentiviral gene
correction for X-linked severe combined immunodeficiency. Blood therapy of murine Wiskott-Aldrich syndrome. Blood 2012;119:
1996;87:3097–102. Available from: http://www.ncbi.nlm.nih.gov/ 4395–407.
pubmed/8605322. 24. Ng YY, Baert MRM, Pike-Overzet K, et al. Correction of B-cell
7. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Role of development in Btk-deficient mice using lentiviral vectors with
interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation codon-optimized human BTK. Leukemia 2010;24:1617–30.
from cord blood hematopoietic progenitor cells and from gamma c 25. Kerns HM, Ryu BY, Stirling BV, et al. B cell-specific lentiviral
transduced severe combined immunodeficiency X1 bone marrow cells. gene therapy leads to sustained B-cell functional recovery in a
Blood 1996;88:3901–9. murine model of X-linked agammaglobulinemia. Blood 2010;115:
8. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for 2146–55.
X-linked severe combined immunodeficiency. N Engl J Med 26. Hagin D, Burroughs L, Torgerson TR. Hematopoietic Stem Cell
2010;363:355–64. Available from: http://www.pubmedcentral.nih.gov/ Transplant for Immune Deficiency and Immune Dysregulation Disorders.
articlerender.fcgi?artid=2957288&tool=pmcentrez&rendertype=abstract. Immunol Allergy Clin North Am 2015;35:695–711.
9. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a 27. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous
polyclonal T Cell pepertoire after gene therapy for X-linked severe CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:
combined immunodeficiency. Sci Transl Med 2011;3:97ra79. 901–10. Available from: http://www.pubmedcentral.nih.gov/articlerender.
10. Hacein-Bey-Abina S, Pai S-Y, Gaspar HB, et al. A modified γ-retrovirus fcgi?artid=4084652&tool=pmcentrez&rendertype=abstract.
vector for X-linked severe combined immunodeficiency. N Engl J Med 28. Porteus MH, Baltimore D. Gene Targeting in Human Cells. Science
2014;371:1407–17. Available from: http://www.nejm.org/doi/abs/ 2003;300(May):75390.
10.1056/NEJMoa1404588. 29. Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative
11. De Ravin SS, Wu X, Moir S, et al. Lentiviral hematopoietic stem cell gene disease after successful correction of CD40 ligand deficiency by gene
therapy for X-linked severe combined immunodeficiency. Sci Transl Med transfer in mice. Nat Med 1998;4:1253–60.
2016;8:335ra57. Available from: http://stm.sciencemag.org/ 30. Pagovich OE, Qui T, Whaley AS, et al. One-time gene therapy for
content/8/335/335ra57.figures-only. hereditary angioedema. Mol Ther 2016;24(Suppl. 1):S298.